Allergy Therapeutics (LON:AGY) Shares Cross Below 200-Day Moving Average – Here’s Why

Shares of Allergy Therapeutics plc (LON:AGY) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 10.23 and traded as low as GBX 10.11. Allergy Therapeutics shares last traded at GBX 10.59, with a volume of 390,663 shares changing hands.

Allergy Therapeutics Stock Performance

The stock has a market capitalization of £670.49 million, a P/E ratio of -10.92, a PEG ratio of -30.70 and a beta of 0.83. The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The company’s fifty day simple moving average is GBX 10.75 and its two-hundred day simple moving average is GBX 10.24.

Allergy Therapeutics (LON:AGY) last released its quarterly earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share for the quarter. The company had revenue of GBX 3,628 million during the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. As a group, equities analysts forecast that Allergy Therapeutics plc will post -2.56 EPS for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.